Company: AGTX
Filing Date: 2025-02-18
Form Type: 10-Q
Source: 0001477932-25-001090
Chunk: 22

Company: Agentix Corp.
Filing Date: 2025-02-18
Form: 10-Q
Item: Part I, Item 2
Chunk 22
---
21,408. The decrease was mainly related to lower consulting fees.

For the three months ended December 31, 2024, we incurred total research and development expenses of $23,287, compared to a gain of $87,304 for the same period in 2023, reflecting a net increase in expenses of $110,591. The 2023 gain was primarily due to a $210,550 charge that was originally billed in March 2023 but subsequently voided during the nine months ended December 31, 2023. This reversal resulted in a one-time credit in the prior period, while the 2024 expenses reflect increased R&D consulting and patent maintenance costs.

For the three months ended December 31, 2024, general and administrative expenses were $16,896 as compared to $25,110 for the three months ended December 31, 2023, a decrease of $8,214. The decrease was primarily related to lower software expenses.

For the three months ended December 31, 2024, foreign exchange loss was $35,784 compared to a gain of $25,434 for the three months ended December 31, 2023, which was due primarily to the fluctuations in currency exchange rates.

For the three months ended December 31, 2024, interest expense, net was $11,295 as compared to $3,214 for the three months ended December 31, 2023. The increase in interest expense related to our loan activity during the three months ended December 31, 2024 as compared to the same period in 2023.

Nine months Ended December 31, 2024 as compared to Nine months Ended December 31, 2023:

We recorded no revenues during the nine months ended December 31, 2024 and 2023.

For the nine months ended December 31, 2024, professional fees were $197,942 as compared to $315,347 for the nine months ended December 31, 2023, a decrease of $117,405. The decrease was mainly related to lower board and consulting fees.

 5Table of Contents

For the nine months ended December 31, 2024, we incurred total research and development expenses of $90,638 as compared to $129,244 for the nine months ended December 31, 2023, a decrease of $38,606. The decrease was primarily due to a $210,550 charge that was originally billed in March